Category: Uncategorized

STEM CELL PROMISE. "Researchers like cardiologist Joseph Wu, MD, PhD, director of the Stanford Cardiovascular Institute, envision a day when stem cells are used not just to treat heart disease, but to quickly identify which medications are most promising for individual patients, or to pinpoint others that are likely to result in cardiac toxicity." http://lnkd.in/dEKiKRn View in LinkedIn

TYPICAL TESTIMONY FOR CORD BLOOD TRANSPLANTS. "Fred Hutchinson Cancer Research Center's Cord Blood Program was launched in 2006. Since then, we have performed more than 200 transplants in patients with malignant and non-malignant diseases who range in age from less than 1 year to 71 years." They have nine ongoing clinical trials today. View in LinkedIn

iPS CELLS INTEGRATED INTO BRAIN. " In some cases, these transplants can lead to functional improvements ... human ES-derived neural cells were transplanted back into models of Huntington's disease or Parkinson's disease and demyelinating disorders ... the most significant recent advances ... in the eye." http://hmg.oxfordjournals.org/content/early/2013/08/19/hmg.ddt379.full View in LinkedIn

THIS SUMMARY OF CELL TRANSPLANT TRIALS, (cord, bone marrow,peripheral blood, and iPS) is surprisingly sparse, given the many thousands of patients that have been treated worldwide. Autologous treatments (the patient's own cells) are considered the lowest adverse risk, and often the diseases have no other options. Most centers advertise their own outcome data separately. http://bloodjournal.hematologylibrary.org/content/122/4/491.full View in LinkedIn

iPS IS POSSIBLE REVOLUTIONARY TREATMENT FOR TOUGH DISEASES. "Examples of specific preclinical applications summarized briefly in this minireview include the use of iPSCs to treat diseases of the liver, nervous system, eye, and heart and metabolic conditions such as diabetes." http://www.jbc.org/content/289/8/4585 View in LinkedIn

2011: FDA TREATS CORD BLOOD AS A BIOLOGICAL DRUG. By 2009, over 22,000 cord blood units (CBUs) were shipped for transplantation, and the majority of the inventory (600,000) are unlicensed CBUs, collected before regulations and now governed by an Investigational New Drug Application (IND) for procedures. http://lnkd.in/dsbbKjN View in LinkedIn

EXPLOSION IN PUBLICATIONS. "Stem cell publications show a Compound Annual Growth Rate (CAGR) of 7.0% from 2008 to 2012, which is more than twice as great as the 2.9% CAGR for global publication output on all topics in the same period ... received 50% more citations." http://lnkd.in/dt7Awxd View in LinkedIn

REGULATION OF CORD BLOOD TRANSPLANTS. "In the United States, the Food and Drug Administration regulates cord blood under the category of “Human Cells, Tissues, and Cellular and Tissue Based-Products.” Several states also require accreditation, including New York, New Jersey, and California." http://en.wikipedia.org/wiki/Cord_blood View in LinkedIn

"REGENERATIVE MEDICINE is a new and expanding area that aims to replace lost or damaged tissues in the human body through either cellular transplantation or endogenous repair. Adult stem cells infused into the circulation are currently leading the clinical front of regenerative medicine." http://hmg.oxfordjournals.org/content/early/2013/08/19/hmg.ddt379.full View in LinkedIn

NO MORE EMBRYONIC ETHICAL ISSUES. "Clearly, using hiPSCs (iPS) in regenerative medicine removes the hESC-associated (embryonic stem cell) ethical issues that resulted in restricted funding of this research in the USA and other countries. It also raises the possibility of autologous transplantation." http://hmg.oxfordjournals.org/content/early/2013/08/19/hmg.ddt379.full View in LinkedIn